Drug Res (Stuttg) 2013; 63(12): 644-649
DOI: 10.1055/s-0033-1358665
Original Article
© Georg Thieme Verlag KG Stuttgart · New York

A Validated Method for Quantifying Entecavir in Biological Matrices and Its Application in a Pharmacokinetic Study in Rats and Dogs

Authors

  • X. Huang

    1   Jiangsu Center for Drug Screening, China Pharmaceutical University, Nanjing, P. R. China
    2   Key Laboratory of Drug Quality Control and Pharmacovigilance (China Pharmaceutical University), Ministry of Education, Nanjing, P. R. China
  • Z.-Z. Jiang

    1   Jiangsu Center for Drug Screening, China Pharmaceutical University, Nanjing, P. R. China
  • W.-W. Tang

    1   Jiangsu Center for Drug Screening, China Pharmaceutical University, Nanjing, P. R. China
  • Y. Xiao

    1   Jiangsu Center for Drug Screening, China Pharmaceutical University, Nanjing, P. R. China
  • L.-Y. Zhang

    1   Jiangsu Center for Drug Screening, China Pharmaceutical University, Nanjing, P. R. China
  • Z.-J. Zhang

    2   Key Laboratory of Drug Quality Control and Pharmacovigilance (China Pharmaceutical University), Ministry of Education, Nanjing, P. R. China
Further Information

Publication History

received 02 May 2013

accepted 05 October 2013

Publication Date:
07 November 2013 (online)

Preview

Abstract

A sensitive and specific liquid chromatography-electrospray ionization-mass spectrometry (LC-ESI-MS) method that uses ganciclovir as an internal standard (IS) has been developed and validated for quantifying entecavir in rat and dog plasma. Following solid-phase extraction (SPE), the analytes were separated on an Inertsil® ODS-3 (5 μm, 150 mm×2.1 mm i.d.) column and analyzed in selected ion monitoring (SIM) mode with a positive electrospray ionization (ESI) source using the [M+H]+ ions, 278.1 for entecavir and 256.0 for ganciclovir. The method was validated over the concentration range of 0.01–9 μg/mL for entecavir. All precisions (RSD) within and between batches were less than 10%, and accuracies ranged from 98.1 to 102.5%. The lower limit of quantification was 0.01 µg/mL. The extraction recovery averaged 93.9–96.7%. The validated method was used for a pharmacokinetic study of entecavir in rats and dogs. The following pharmacokinetic parameters were obtained for rats and dogs, respectively: the area under the plasma concentration vs. time curves from time 0 to 24 h (AUC0–24) were 15.4±4.5 and 23.4±7.2 μg∙h/mL; the mean maximum plasma concentration (Cmax) were 2.4±0.8 and 5.0±0.9 μg/mL; the mean time to reach the maximum plasma concentrations (Tmax) were 1.7±0.7 and 1.5±0.4 h; and the mean elimination half-life (t1/2) were 5.3±1.4 and 3.8±1.3 h.